Prevention of postoperative recurrence of Crohn's disease

详细信息	查看全文 | 推荐本文 |

• 作者：E.S. van Loo^a ; ^{e.s.van.loo@umcg.nl} ; G. Dijkstra^b ; R.J. Ploeg^c ; V.B. Nieuwenhuijs^c
• 关键词：CD ; Crohn's Disease ; CDAI ; Crohn's disease Activity Index ; CI ; Confidence Interval ; IL-10 ; Interleukin-10 ; E&ndash ; E ; End-to-end ; S&ndash ; S ; Side-to-side ; S&ndash ; E ; Side-to-end ; LoE ; Level of Evidence ; GoR ; Grade of Recommendation
• 刊名：Journal of Crohn's and Colitis
• 出版年：2012
• 期刊代码：pca215_18739946
• 类别：med
• 出版时间：July, 2012
• 卷：6
• 期：6
• 页码：637-646
• 文件大小：739 K

摘要

Background

Up to 75%of patients with Crohn's disease (CD) will have intestinal resection during their life. Most patients will, however, develop postoperative recurrence (endoscopic, clinical or surgical). Several medical and surgical strategies have been attempted to prevent postoperative recurrence. This review evaluates the efficacy of different drug regimens and surgical techniques in the prevention of clinical, endoscopic and surgical postoperative recurrence of CD.

Methods

A literature search for randomized controlled trials on medical or surgical interventions was performed. The endpoints for efficacy were clinical, endoscopic and surgical recurrence. Meta-analyses were performed in case two or more RCTs evaluated the same drug or surgical technique.

Results

Mesalamine is more effective in preventing clinical recurrence than placebo (P = 0,012), as well as nitroimidazolic antibiotics at one year follow-up (P < 0.001) and thiopurines (P = 0.018). Nitroimidazolic antibiotics are also more effective than placebo in preventing endoscopic recurrence (P = 0.037), as well as thiopurines (P = 0.015) and infliximab (P = 0.006). Budenoside, probiotics, Interleukin-10 nor any of the different surgical procedures showed any significant difference compared to placebo in postoperative recurrence rates of CD.

Conclusion

Among the different drug regimens and surgical techniques, only thiopurines and nitroimidazolic antibiotics are able to reduce postoperative clinical as well as endoscopic recurrence of CD. Mesalamine and infliximab also seem to be superior to placebo in preventing clinical recurrence and endoscopic recurrence, respectively. There is a paucity of trials evaluating long-term follow-up and prevention of surgical recurrence of CD.